CliffBio
biologic

Hemlibra

emicizumab-kxwh

Loss of exclusivityNovember 2029projected — 12-year biologic exclusivity estimate
CompanyGenentech →View the full company profile on CliffBio

Drug detail

Brand nameHemlibra
Active ingredientemicizumab-kxwh
Strength105MG/0.7ML
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalNovember 2017
Marketing statusRx

More from Genentech

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Hemlibra patent cliff — loss of exclusivity November 2029 | CliffBio